Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05571059 · ClinicalTrials.gov registry record · Phase 2
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Cumberland Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
- 19
- Study locations
NCT05571059 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by Cumberland Pharmaceuticals. The registered enrollment target is 128 participants, below the 749-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (83% lower). The trial reports 19 study locations across 15 states.
The verdict
NCT05571059, a Phase 2 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by Cumberland Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
- 19
- Study locations
Study Summary
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ifetroban Sodium
Study Locations (19)
California
- Biosolutions Clinical Research - La Mesa
- University of California San Francisco - San Francisco
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Miami VA Health System - Miami
New York
- Icahn School of Medicine at Mount Sinai - New York
- University of Rochester - Rochester
Texas
- Baylor University Medical Center - Dallas
- Premier Pulmonary Critical Care and Sleep Medicine - Denison
Illinois
- Northwestern Medicine - Chicago
Indiana
- Indiana University Health - Indianapolis
Kansas
- University of Kansas - Kansas City
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05571059
The ClinicalTrials.gov registry entry for NCT05571059 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 749-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (83% lower). The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05571059 reports 19 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05571059 about?
NCT05571059 is a clinical study titled "Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)". Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
What is the current status of trial NCT05571059?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2024-01-31. Estimated completion is 2027-01.
What conditions does trial NCT05571059 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT05571059?
The interventions under investigation include: Placebo (DRUG), Ifetroban Sodium (DRUG).
Who is sponsoring clinical trial NCT05571059?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05571059 being conducted?
This trial has 19 study locations across California, Florida, Illinois, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
RECRUITING · Phase 2
-
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.